Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

/in

Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate Strasbourg, France – Montreal, Canada – Boston, United States, November 13, 2025: Domain Therapeutics […]

Read more

Blue Cell Therapeutics appoints leading cell therapy executive Miguel Forte MD, PhD, to its Board of Directors

/in

Miguel Forte, current President of the International Society for Cell & Gene Therapy (ISCT), joins Blue Cell as a Non-Executive Director Highly experienced executive with deep scientific expertise, who has helped lead numerous private and public cell therapy biotechs, establishing corporate structures and raising funds Appointment comes as Blue Cell advances its groundbreaking “off-the-shelf” allogeneic […]

Read more

Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates  

/in

Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very favourable safety profile Commit Biologics’ CEO Mikkel Wandahl Pedersen to present data at PEGS Europe summit, November 11-13, 2025 in Lisbon, Portugal Aarhus, Denmark, November […]

Read more

Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours

/in

Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control observed in multiple patients at lowest dose evaluated to date Enrolment continues in dose-escalation segment of the AERIAL trial with additional data for LEU011 anticipated during the first half of 2026 Poster presentation of AERIAL trial […]

Read more

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025

/in

New clinical data from the MATCH Phase II study shows early improvement in liver function after treatment with non-engineered macrophages is associated with positive long term clinical outcomes New preclinical data from Resolution’s first engineered Regenerative Macrophage Therapy, RTX001, shows significant reduction of systemic inflammation Comes as Resolution progresses its Phase I/II EMERALD study of […]

Read more
© Optimum Strategic Communications.